SCHEMBL7081409

SCHEMBL7081409

Cc1ccc(C(=O)NCCO)c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
RPS6KB1 P23443 1/20 0.45
KDR P35968 1/20 0.45
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 3/20 0.43
EIF2AK2 P19525 1/20 0.42
RECQL P46063 1/20 0.42
MAP4K4 O95819 1/20 0.42
CLK2 P49760 1/20 0.42
DYRK1A Q13627 1/20 0.42
SRPK1 Q96SB4 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083122 0.89 RPS6KB1 (0.49) SYKPDGFRBPDGFRARPS6KB1KDR
SCHEMBL7081591 0.87 SYK (0.43) SYKPDGFRBPDGFRARPS6KB1KDR
SCHEMBL7081452 0.86 SYK (0.50) SYKPDGFRBPDGFRAKDRKDM4E
SCHEMBL7078467 0.85 PDGFRB (0.56) SYKPDGFRBPDGFRANPC1RAB9A
SCHEMBL6608523 0.84 SYK (0.48) SYKPDGFRBPDGFRARPS6KB1KDR
SCHEMBL7081454 0.83 SYK (0.53) SYKRPS6KB1KDRKDM4ENPC1
SCHEMBL7077905 0.83 PDGFRB (0.67) PDGFRBPDGFRAKDRKDM4ENPC1
SCHEMBL7082077 0.83 SYK (0.52) SYKPDGFRBPDGFRARPS6KB1KDR
SCHEMBL7077410 0.83 SYK (0.52) SYKKDRKDM4ENPC1RAB9A
SCHEMBL7083647 0.83 SYK (0.48) SYKPDGFRBPDGFRAKDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US disclosed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT SYK 4369/4885PDGFRB 3908/4885PDGFRA 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.